The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention – A prospective, randomized, double-blinded, placebo-controlled, phase IV pilot trial (STEMILAND-1)
Key facts
- Where
- Vienna, AusztriaSee the site
- Phase
- 4. fázis
Where in Ausztria
- Klinik LandstrasseVienna, AusztriaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University Of Vienna
- Trial code
- EU 2025-523676-23-00
- Record updated
- 2026. szeptember 16.
- Original description
The primary objective is to evaluate the feasibility of very early continuous i.v. administration of the highly cardioselective betablocker Landiolol in anterior/lateral ST-elevation acute coronary syndrome (STE-ACS).Read full original descriptionShow less
The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention – A prospective, randomized, double- blinded, placebo controlled, phase IV pilot trial (STEMILAND-1)
The primary objective is to evaluate the feasibility of very early continuous i.v. administration of the highly cardioselective betablocker Landiolol in anterior/lateral ST-elevation acute coronary syndrome (STE-ACS).
Inclusion: Anterior or lateral ST-elevation acute coronary syndrome (STE-ACS; defined as ST-segment elevation in two or more of precordial leads V1-V6, and I and aVL, representing anterior wall infarction or ischemia); Treated at our study center; Age >= 18 years; Hemodynamically stable (MAP >60 mmHg, heart rate > 70/min); Oral and written informed consent.
Exclusion: Known pathologies of the cardiac electrical conduction system (e.g., sick-sinus-syndrome, AV-block II° or III°); Acute heart failure and cardiogenic Shock (Killip Classes III and IV); Allergy or insensitivity to ß-blockers; Known pulmonary hypertension; Heart rate < 50 bpm; Known or suspected pregnancy; Acute asthma exacerbation; Severe metabolic acidosis; Known pheochromocytoma; Anticipated time to wire-crossing >120 minutes after first medical contact; Thrombolysis candidate as defined by treating physician.